Sharing information at the symposium is what it’s all about. Today, Randall Kaye, chief medical officer from Avanir Pharmaceuticals, chose the symposium to give a presentation on a newly approved FDA drug for emotional lability (uncontrollable laughter and crying) called Nueudexta. Emotional lability is a symptom that is experienced by some people living with MND.
Nuedexta is actually a combination of two drugs, dextromethorphan and quinidine, that are already quite well known. In a clinical trial involving over 300 people with MND or multiple sclerosis, Nuedexta was found to significantly reduce the frequency and severity of episodes of uncontrollable laughter and crying. As Nuedexta has recently been approved by the FDA, this symposium gave Avanir Pharmaceuticals the opportunity to provide delegates with an overview of Nuedexta and guidelines on how it should be used.
We have been told by Avanir Pharmaceuticals that talks will begin with the European regulatory authorities in 2011. It is not yet possible to say when Nuedexta will be available to people with MND in the UK.
We will keep you posted as soon as we hear developments on the availability of this drug in the UK.